Analysis of these genetic variants, that are associated with both dyslipidemia and differential serum or urine metabolite levels (e.g., rs35570672-T) (Tables 1, 2), demonstrate that the risk alleles of NAT2 for dyslipidemia are associated with higher NAT2 activity (i.e., rapid NAT2 acetylator phenotype). Here, NAT2 is linked to metabolic syndrome.